The US Advanced Research Projects Agency for Health, ARPA-H, has announced contracts with three development teams and an independent testing organization under BoSS, a program aiming to preserve cell-based products at room temperature. The planned investment is up to $87 million over four years. Teams from companies, universities and other organizations will work toward milestones defined for each stage of development. Official announcement ↗

The aim is not to improve insulated shipping containers. The teams are seeking ways to suppress cellular metabolism and combine protective materials, drying techniques and other approaches so that cells can recover the functions they need after room-temperature storage. The work spans preservation agents, cell-processing equipment and manufacturing processes. Program overview ↗

ATCC, which will conduct independent testing, preserves and supplies cells and microorganisms and also offers services such as cell authentication and contamination testing. For this program, it will supply cells for shared evaluations and assess survival, function and other properties after storage, independently of the development teams. ATCC services ↗

What stands out is where the research funding is going: not toward a new therapeutic target, but toward storage and transport constraints shared by multiple cell therapies. Even without changing the treatment itself, a technology that makes it easier to handle can give pharmaceutical companies and contract manufacturers a reason to adopt it.

Keep following this topic

v1 ·

Transporting Cell Therapies Without Refrigeration

BoSS announced three development teams and independent testing by ATCC, with up to $87 million planned over four years.

  1. Reports and agreements reviewedRecorded
  2. Further validationUnverified
  3. Adoption and benefitUnverified
NEXT CHECK

Storage duration by cell type, recovered function and independent ATCC testing.

Hypothesis and what would change it

Improving shared preservation processes could create demand beyond the development of individual therapies.

What would change our view: Reconsider if viable cells fail to recover required functions, or adoption costs outweigh convenience.

This is a development funding plan, not a report of practical room-temperature preservation.

Evidence, organizations & history →

Following saves this topic to your account. It does not send email or push notifications.

Evidence & reading

Public sources checked for this edition. Linked pages may subsequently change.

  1. 公式発表 ↗arpa-h.gov · recorded 2026-09-29
  2. プログラム概要 ↗arpa-h.gov · recorded 2026-09-29
  3. ATCCのサービス ↗www.atcc.org · recorded 2026-09-29

READER DISCUSSION

What does this change for you?

A question, a different reading, or a source we should consider. A short comment is welcome.

Comments are public only after editorial review. Comments, likes and reports are for people aged 18 or older. Sign-in is required; you choose a public display name. Reviews are not continuous. Discussion rules

Loading discussion…

Also in this issue

Contents →